SYMBIO - Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More!
PI3K inhibitors and clinical data of Bendamustine +other drugs in chronic lymphocytic leukemia (CLL) and other leukemias were the flavor at ASH ‘12 and at the 31st JP Morgan Healthcare conference. The positive impact of these was seen in the small cap Japanese company SymBio Pharma (4582) whose stock has gone up by ~185% since our initiation on September 14th 2012. SymBio’s focus on Japan and select Asia Pacific Rim countries market along with its pipeline makes it attractive to companies seeking presence in these geographies. We currently attribute this impact to the investment it received from PE Whiz Partners in the form of convertible bonds and promising future potential of its product portfolio. For more details, please read our report released on 16th January. 2013 on SymBio titled “Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More!”
